An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...

PSMA PET-CT is a diagnosit tool helping save men's lives with prostate cancer that has spread beyond the prostate gland Dr. David Samadi says that men with aggressive prostate cancer or a very high ...

Daniel Oguna, a PET CT technologist prepares a patient for a scan procedure at Aga Khan University Hospital, Nairobi. [Photo: Standard] The latest and most advanced scan for evaluation of patients ...

Approximately 20% to 40% of men who have surgery for localized prostate cancer will see the cancer return within 10 years, often first detected by a rising PSA blood test. When this happens, doctors ...

Visual Abstract. Overall survival for patients treated with salvage radiotherapy: real world data from an entire country. A patient with biochemical recurrence after radical prostatectomy and no ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

A world-first trial of Australian men has confirmed a specialised scan can accurately “light up” prostate cancer, saving unnecessary and painful biopsies and stress of over-diagnosis.

More than 100,000 future cancer cases were projected to result from the 93 million CT examinations performed in 2023, according to a study published April 14 in JAMA Internal Medicine. Low-dose CT ...